241
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon

, &
Pages 73-83 | Received 05 Feb 2010, Accepted 09 Aug 2010, Published online: 05 Oct 2010
 

Abstract

Novel ‘beads-in-a-tablet’ formulations (total weight ∼ 740–780 mg) have been prepared that meet USP 31 requirements for Delayed Release of mesalamine. Several methods are presented that overcome breakage of beads during tablet compaction were explored. Bead formulations comprise a combination of extrusion and spheronization to produce a relatively high drug load (80%), followed by coating (25%) with a colonic-targeted drug release polymer (polymethacrylates, Eudragit® S100), overcoated (3%) with hydroxypropyl methylcellulose (Opadry®) to improve bead binding and compactability, and using 20% coat of lactose/sodium starch glycolate (Explotab®) as binder/disintegrant/cushioning agent, thus allowing a sufficiently thick coating to be uniform and without being broken during tablet compaction. Then, the aforementioned beads were compressed into tablets at 1500 pounds of pressure containing 400 mg of mesalamine, and finally coating the compressed tablets with Surelease® (ethylcellulose):Opadry® = 1:0.5 ranging from 1.5–2.5% weight gain; the resulting tablets met USP 31 dissolution requirements for delayed release tablets.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.